MONARCH 3:阿贝西利作为晚期乳腺癌初始治疗
MONARCH 3是一项双盲随机III期研究,纳入493例绝经后HR阳性/HER2阴性晚期乳腺癌患者,比较阿贝西利或安慰剂联合非甾体芳香化酶抑制剂一线治疗。阿贝西利组中位无进展生存期显著延长(HR 0.54;95%CI 0.41-0.72;
要点
- 阿贝西利联合非甾体芳香化酶抑制剂显著延长一线HR阳性/HER2阴性晚期乳腺癌的无进展生存期。
- 可测量病灶客观缓解率阿贝西利组59%,安慰剂组44%。
- 最常见不良事件为腹泻(81.3%),主要为1级(44.6%)。
核心结论
- 阿贝西利联合非甾体芳香化酶抑制剂作为初始治疗有效,显著改善HR阳性/HER2阴性晚期乳腺癌女性的无进展生存期和客观缓解率,并显示可耐受的安全性。
研究设计与样本
- MONARCH 3为双盲、随机III期研究,纳入493例绝经后HR阳性/HER2阴性晚期乳腺癌患者,既往未接受晚期系统治疗。
- 患者接受阿贝西利或安慰剂(150 mg每日两次连续给药)联合阿那曲唑1 mg或来曲唑2.5 mg每日一次。
- 主要终点为研究者评估的无进展生存期;次要终点包括缓解评估和安全性;计划期中分析在189个事件后进行。
主要发现
- 阿贝西利组腹泻最常见(81.3%),主要为1级(44.6%)。
- 阿贝西利组 vs 安慰剂组最常见的3或4级不良事件:中性粒细胞减少(21.1% vs 1.2%)、腹泻(9.5% vs 1.2%)、白细胞减少(7.6% vs 0.6%)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm ( P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
引用
- Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017. PMID: 28968163. doi:10.1200/JCO.2017.75.6155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。